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Abstract
Numerous strategies have been managed to improve functional recovery after spinal cord injury (SCI) but an optimal
strategy doesn’t exist yet. Actually, it is the complexity of the injured spinal cord pathophysiology that begets the
multifactorial approaches assessed to favour tissue protection, axonal regrowth and functional recovery. In this context, it
appears that mesenchymal stem cells (MSCs) could take an interesting part. The aim of this study is to graft MSCs after a
spinal cord compression injury in adult rat to assess their effect on functional recovery and to highlight their mechanisms of
action. We found that in intravenously grafted animals, MSCs induce, as early as 1 week after the graft, an improvement of
their open field and grid navigation scores compared to control animals. At the histological analysis of their dissected spinal
cord, no MSCs were found within the host despite their BrdU labelling performed before the graft, whatever the delay
observed: 7, 14 or 21 days. However, a cytokine array performed on spinal cord extracts 3 days after MSC graft reveals a
significant increase of NGF expression in the injured tissue. Also, a significant tissue sparing effect of MSC graft was
observed. Finally, we also show that MSCs promote vascularisation, as the density of blood vessels within the lesioned area
was higher in grafted rats. In conclusion, we bring here some new evidences that MSCs most likely act throughout their
secretions and not via their own integration/differentiation within the host tissue.
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Introduction
Treatment of spinal cord injury (SCI) faces several problems.
First of all, the mechanical damage and axonal disruption in the
spinal cord are followed by a progressive cascade of secondary
deleterious reactions spreading to the adjacent spared tissue
leading to lesion extension and worsening the situation [1].
Secondly, although axonal regeneration is initiated, it is quickly
repressed due to the inhibitory environment acting as a chemical
and physical barrier for repair [2]. In this context, the self-
regeneration and reorganization ability of the central nervous
system is insufficient to lead to considerable functional improve-
ments.
Numerous strategies have been managed to improve functional
recovery after SCI. These studies focused on neuroprotection or
axonal regeneration, by modifying the injured environment to be
beneficial for repair, by replacing lost cells, stimulating and
guiding axonal growth or boosting remyelination [3,4,5,6]. To act
on these events, scientists often exploited the potential of cell
therapy using transplantation of various cell types like Schwann
cells [7,8], olfactory ensheathing cells [9,10], neural stem cells
[11,12], bone marrow stromal cells [13,14], fibroblasts [15,16] and
macrophages [17]. Despite promising results, it ensues from these
experiments and from the complexity of SCI that an optimal single
focalized strategy to treat it efficiently doesn’t exist. It becomes
evident that research has to concentrate its effort on multifactorial
treatments, playing on the different factors of SCI pathophysiol-
ogy. In this context, it appears that bone marrow stromal cells, also
called mesenchymal stem cells (MSCs) could take an interesting
part in these strategies.
Indeed, MSCs are adult stem cells with self-renewing and
differentiation abilities [18]. These cells are harvested from bone
marrow and easily and quickly expanded in vitro. This accessibility
makes them an interesting candidate for autologous transplanta-
tion, abolishing immune and ethical problems of embryonic/foetal
stem cell grafts [19]. MSCs are also able to modulate the CNS
injured environment and to promote repair as they secrete anti-
inflammatory, anti-apoptotic molecules and trophic factors able to
support axonal growth, immunomodulation, to promote angio-
genesis, remyelination and to protect from apoptotic cell death
[20,21,22,23]. In addition, some evidence suggests that MSCs may
be able to differentiate into neuronal cells in vitro using co-culture
[24,25] or differentiation medium [26,27,28] but also in vivo after
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neuronal cell replacement strategies.
Different modes of administration have been used for cell
transplantation after SCI: intrathecal [30], intravenous [13] or
intraspinal [31]. For a human application, intravenous injection
appears to be the easiest way to bring therapeutics to patient
without risking further damage to the spinal cord. Furthermore,
MSC intravenous injection is safe, as it has been shown to have no
adverse effect like obstruction of blood circulation or tumorige-
nicity [32,33].
The aim of this study was to graft MSCs by intravenous
injection one week after a spinal cord compression injury, in order
to assess their effect on functional recovery and find by which
mechanisms these cells exert their beneficial effect.
Results
1. Characterisation of rat MSCs in vitro
MSCs were isolated from Wistar adult female rats and cultured
in plastic adherent conditions, classically used for MSCs in vitro
expansion. They were characterized according to three criteria:
adherence to tissue culture plastic dish, specific surface antigen
expression and multipotent differentiation ability. MSCs exhibited
typical elongated, fibroblast-like morphology or large, flattened
shape (figure 1A). After 4–5 passages (P4–P5), all cells express
surface antigens CD90 (figure 1B) as well as the neurotrophin co-
receptor p75NGFr, also known as CD271 (figure 1C) [34], while
they were negative for CD45 and CD11b (figures 1D and 1E). P4
MSCs are multipotent, as they differentiate into adipocytes and
osteocytes according to published protocols (figures 1F and 1G)
[35]. After 12 passages, cells were deprived of serum to induce the
expression of nestin (figures 1H), a protein expressed by neural
stem cells. This strategy was used in order to influence their fate
towards a neural phenotype. Indeed, it has been demonstrated
that only nestin-positive MSCs were able to differentiate into
functional neurons in vitro [24]. The transcriptomic and proteomic
comparisons of nestin-positive and nestin-negative MSCs also
suggest that the nestin-positive cell population contains a higher
percentage of stem cells that would adopt a neural fate [36]. It thus
seemed appropriate to use these nestin-positive cells in our
transplantation strategy.
2. BrdU labelling of MSCs
We used in vitro BrdU incorporation to label MSCs before graft.
After 72 h of culture in presence of 1.10
26M BrdU, we confirmed
by immunocytochemistry that all MSCs were labelled with BrdU
(figure 2A). We also assessed the maintenance of the BrdU
labelling in MSCs with time to take into account cell population
doublings and cell passages. We show that 3 and 7 days after the
removal of BrdU from the culture medium, which respectively
correspond to 0 and 1 passage, BrdU is still easily detected within
the MSCs (figures 2B–C). After 21 days, and 6 passages, the signal
is clearly reduced, but remains observable (figure 2D).
3. Fate of grafted cells
To study the fate of grafted cells, we performed, at 7, 14 and
21 days after the graft, a BrdU immunohistochemistry on the
injured transplanted spinal cord, but also on lung, liver, spleen and
kidney tissue sections, as MSCs were grafted in the tail vein.
Unfortunately, no grafted cell could be found within the lesion site
neither in any organs (data not shown). In order to rule out a
problem of BrdU detection, we also performed BrdU immuno-
histochemistry on spinal cord sections from rats that received,
during 3 consecutive days following SCI, intraperitoneal BrdU
injection (100 mg/kg), and were allowed to survive for 2 more
weeks. Figure 2E shows that BrdU is detected within the injured
spinal cord, demonstrating that our protocol of detection is
efficient.
4. Control of MSC viability and CD profile
To confirm cell viability at the time of iv injection, we placed
back into culture the last drop of the MSC suspension from the
injection needle and characterized them 24 hours later by
immunocytochemistry for nestin and p75NGFr. Transplanted
cells were viable at the time of injection as they still could adhere
to plastic culture flask and express nestin and p75NGFr (figures 3
A–B). As transplanted cells were P12 MSCs, we checked that their
CD profile was still the one that characterizes MSCs, and thus
performed CD90, CD271, CD45 and CD11b immunocytochem-
istry on P12 MSCs (figures 3 C–F). The results confirm that P12
MSCs have conserved their CD profile, as they do still express
CD90 and CD271, and are still negative for CD45 and CD11b.
5. MSC graft improves functional recovery after spinal
cord compression injury
Spinal cord injured animals were submitted to 2 behavioural
assessments in order to evaluate the effect of MSC graft on
functional recovery. Locomotor skills were assessed by the open
field test using the BBB rating scale. Mean scores over time were
higher in the MSC grafted group (injured + MSC) compared to
control groups (injured + vehicle or injured only). The difference
between MSC grafted and control groups was statistically
significant (injured + MSC vs injured only p=0.0029; injured +
MSC vs injured + vehicle p,0.0001; figure 4A). Moreover, only
MSC grafted animals reached and overtook the score correspond-
ing to weight support stepping (score of 9). Interestingly, locomotor
scores from MSC grafted rats begun to be distinguishable from
control groups already three days after the graft. The grid
navigation test completes this behavioural part of motor recovery
assessment. Even if grafted rats did not recover their toe control
and the capacity to realise fine movements, their scores were
significantly improved with MSC graft (injured + MSC vs injured
only p,0.0001; injured + MSC vs injured + vehicle p,0.0001;
figure 4B).
6. MSC graft increases NGF level expression within the
injured tissue
As behavioural improvements appear already during the first
week following MSC graft, we performed cytokine array on
proteins extracted from the injured spinal cord of control and
MSC-treated rats (3 days post-graft), to assess and compare
changes in cytokine/trophic factor expression. We analyzed the
expression of Ciliary neurotrophic factor (CNTF), Granulocyte
macrophage-colony stimulating factor (GM–CSF), Interleukin-1
alpha (IL–1a), Interleukin21 beta (IL–1b), Vascular endothelial
growth factor (VEGF), Nerve growth factor beta (ßNGF),
Interleukin-10 (IL–10), Interferon-gamma (IFN-c), Monocyte
chemo-attractant protein-1 (MCP–1) and Tumor necrosis factor
alpha (TNF–a). The expression levels of all these molecules were
higher in grafted animals compared to vehicle-treated animals.
The sole factor for which we observed a difference statistically
significant is ßNGF (p=0.042) (figure 5A). All other tested
molecules showed only a slight increase tendency. As SCI is
known to trigger NGF up-regulation by itself, the higher rate of
NGF expression obtained 3 days after the graft in the ‘‘injured +
MSC group’’ compared to the ‘‘injured + vehicle-treated group’’,
raises the hypothesis that the source of this increased NGF are the
Mesenchymal Stem Cells for Spinal Cord Injury
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e39500Figure 1. Mesenchymal stem cell characterization. (A): Phase contrast microphotography of rat MSCs in culture. Cells exhibit typical elongated,
fibroblast-like morphology (arrowheads) or large, flattened shape (asterisks). (B) CD90 and (C) CD271 positive immunofluorescent labelings of P4
MSCs in culture, while CD45 (D) and CD11b (E) immunostainings are negative. (F) Adipogenic differentiation of P4-MSCs revealed with Oil Red O. (G)
Alizarin Red staining of P4 MSCs induced to osteocytes reveals mineral deposition. (H) Immunofluorescent visualization of nestin induction in P12-
MSCs deprived of serum. Nuclei are labeled with the Vectashield-DAPI mounting medium.
doi:10.1371/journal.pone.0039500.g001
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performing an ELISA assay on P12-MSC conditioned medium.
The analysis of 2 different culture media (from 2 distinct cultures)
demonstrates that MSCs secrete the neurotrophin NGF (figure 5B).
Immunocytochemistry for NGF on P12 MSCs in culture also
reveals that all of them express NGF in vitro (figure 5C). In parallel,
ELISA for BDNF was performed on the same culture media,
showing that MSC do also secrete BDNF, but in a much lower
quantity compared to NGF (figure 5B). This correlates with the
Figure 2. BrdU immunodetection. (A) BrdU (FITC)-DAPI immunostaining on MSCs cultured with 1.10
26M BrdU for 72 h, demonstrating that cells
were all labeled before being transplanted. (B–C–D) BrdU (Rhodamine) maintenance in MSCs 3 days (B), 7 days (C) and 21 days (D) after the removal
of BrdU from the culture medium. (E) BrdU immunodetection (FITC) on a longitudinal spinal cord tissue section from a rat that received 3 ip BrdU
injections after spinal cord injury. Scale bar: 50 mm (A), 100 mm (B, C, D) and 200 mm (E).
doi:10.1371/journal.pone.0039500.g002
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MSCs in vitro (figure 5D).
7. MSC graft promotes tissue sparing after spinal cord
compression injury
To further elucidate the mechanisms that could explain the
beneficial effects obtained with MSC transplantation, we investi-
gated the possibility of a tissue sparing effect. We thus performed a
histological luxol fast blue/eosin staining on serial cross sections
from injured spinal cord at 28 days after injury, in MSC grafted
and in control ‘‘injured-only’’ rats. Sections were then analyzed
and the ratio ‘‘injured area/total area’’ from each section
determined. (figures 6A–B). The mean values were reported on
figure 6C. This analysis revealed a reduced surface of damaged
Figure 3. MSC viability and CD profile. Nestin (A) and p75NGFr (B) immunofluorescent stainings on MSCs: The last drop of MSC suspension from
the injection needle was placed back into culture to check their viability at the time of injection. (C–F): CD profile of P12 MSC grafted cells, showing
their immunoreactivity for CD90 (C) and CD271 (D), and the absence of CD45 (E) and CD11b (F) expression. Scale bar: 50 mm (A, B), 100 mm (C–F).
doi:10.1371/journal.pone.0039500.g003
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matter and grey matter together). The difference was statistically
significant (p=0.0454). It thus strongly supports a neuroprotective
effect of the MSC graft.
8. MSC graft does not increase axonal regrowth
We analysed the effect of MSC graft on axonal regrowth
21 days after transplantation, by an immunostaining against GAP-
43 on transversal spinal cord sections taken at the level of the
lesion site (figures 7A–B). The quantification of the proportion of
the total surface of the section stained for GAP–43 doesn’t show a
significant difference between control (2,25%60,44) and grafted
(2,96%60,35) animals, though these latter exhibit higher values of
GAP-43 immunoreactivity (figure 7C; p=0.23 Student’s t-Test).
9. MSC graft favours vascularisation
To assess a potential effect of MSC graft on tissue vascularisa-
tion, we performed a RECA-1 immunostaining, a specific marker
Figure 4. Behavioral analysis. (A) Locomotor scores as assessed by the BBB rating scale. MSC grafted rats reach significantly higher scores
compared to both control groups. Only MSC transplanted rats reach the weight-supporting step level (score of 9). Injured + MSC vs injured only
p=0.0029; injured + MSC vs injured + vehicle p,0.0001. (B) Grid test scores assessing deficits in descending fine motor control. MSC grafted rats
reach higher scores, significantly different from control rats. Injured + MSC vs injured only p,0.0001; injured + MSC vs injured + vehicle p,0.0001.
doi:10.1371/journal.pone.0039500.g004
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centred on the lesion, both on MSC-treated and control groups
(3 days after MSC or vehicle treatment). A first qualitative analysis
revealed a higher number of blood vessels in the injury epicentre of
MSC-treated cords compared to controls (figures 8 A–B).
Quantification confirmed a significant increase in the number of
blood vessels in the injury site of grafted animals compared to
controls (figure 8C). Despite the higher surface analysed in the
control group (which correspond to the injured tissue:
2.067.3786198.630 mm
2 for injured + MSC and 2.207.1016
212?647 mm
2 for vehicle-treated), the number of blood vessels is
lower in that group compared to injured + MSC group.
Discussion
Our work confirms that MSC treatment is beneficial after SCI
and is in accordance with previous studies reviewed by [4]. We
show by two complementary locomotor tests that MSCs have the
ability to significantly improve functional recovery. Using the open
field test with the BBB rating scale, we were able to precisely study
locomotion faculties after SCI. The animals grafted with MSCs do
not only reach higher motor scores, but were also able to support
Figure 5. Cytokine array and Elisa results. (A) Cytokine arrays. Spinal cord extracts from injured vehicle-treated (n=4) and MSC-treated (n=5)
rats. ß-NGF is significantly increased within the lesioned site 3 days after MSC injection compared to controls. * p,0.05 (mean6S.E.). (B) Histogram
showing the amounts, in pg/ml, of the neurotrophins NGF and BDNF as quantified by Elisa, within 2 distinct P12 MSC-conditioned media (M1 and
M2). (C) NGF and (D) BDNF fluorescent immunocytochemistry on P12 MSCs in vitro. Scale bar : 50 mm.
doi:10.1371/journal.pone.0039500.g005
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were not able of weight support and seemed to reach a plateau.
MSCs appear to act quickly after iv injection as the difference of
recovery of MSC-grafted animals and control groups is already
important 3 days after the cell injection (BBB scores of 4.5 and 2.6
respectively). We also show a beneficial effect of MSCs on the grid-
walking task. Again, MSC-grafted rats obtained higher scores than
controls, reinforcing the conclusion that MSCs do really exert a
beneficial effect on recovery after SCI. According to the literature
[37], the evidence of a functional improvement after iv injection of
MSCs in SCI is scarcely described. Indeed, our results can be
compared to one single study, conducted by Urdzikova et al, who
also described locomotor improvement after bone marrow stromal
cell iv injection performed one week after a thoracic compression
injury [38]. Their behavioral data also demonstrate a rapid effect
of the treatment, but no evidence of MSC integration within the
host tissue to replace lost cells has been described, even if some
grafted MSCs could be found within the lesioned tissue.
In spite of the efficacy and maintenance of the BrdU labeling of
MSCs, the use of an effective protocol to detect BrdU in vivo, and
the confirmation of the viability of the cells at the time of injection,
we were not able to find the grafted MSCs at various delays (7, 14
and 21 days post injection) in the injured spinal cord, neither in
highly vascularized organs such as lungs, liver, spleen and kidneys
where we thought the cells could have migrate after systemic
injection [39,40]. These observations are in accordance with Karp
and Teo analysis of exogenously infused-MSC homing [41].
Indeed, according to this review, the homing of cultured-expanded
iv-injected MSCs is inefficient, and apparently due to (i) a lack of
relevant cell adhesion and chemokine receptors and (ii) to the
increased size of MSCs in culture, which likely promotes cell
entrapment and reduces the number of MSCs that reach the
target site. If homing towards the injury site of MSCs delivered by
iv injections has nevertheless been reported in SCI [13,38,42] as
well as in brain injuries [40,43], these cells reach the host tissue in
small numbers and are not sufficient to explain the rapid
functional recovery [44]. It thus seems clear that iv delivery of
MSCs is not the most effective way to introduce cells after injury
(see also [45,46]) but it nevertheless remains the least invasive,
making it worth trying. Other delivery methods (intra-thecal,
intra-arterial) might have better potential in the perspective of
clinical application [47]. Yet, it remains that even if we couldn’t
find grafted cells in the host tissue, we observed a clear, significant
and early beneficial effect of MSC iv transplantation on
locomotion, strongly suggesting that MSCs act throughout their
secretions. Likewise, several reviews on the paracrine therapeutic
effect of MSCs [4,20,21,23] reinforce our findings.
To explore this hypothesis of an early paracrine effect of the
MSCs, we performed cytokine array on the injured tissue 3 days
post injection. Among the cytokines analyzed, we observed a slight
increase in the expression of CNTF, MCP-1 and GM-CSF. CNTF
plays a role in neuroprotection [48] and promotes survival and
Figure 6. Neuroprotection. MSC transplants favor tissue sparing after SCI. Luxol fast blue/hematoxylin staining on cross sections of MSC-grafted
(A) and control injured only (B) rats, 21 days after transplantation. The quantification of spared tissue (C), as assessed by the mean ratio of injured
area on total area of the sections, reveals a significant decrease of the lesion extension in MSC treated rats compared to control ones. * p,0.05.
doi:10.1371/journal.pone.0039500.g006
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[49]. MCP-1 induces monocyte recruitment during inflammation
[50], enhancing myelin debris clearance in CNS injuries [51].
GM-CSF activates macrophages [51], inhibits apoptosis of
neuronal cells and gliosis after SCI [52,53] and treatment with
GM-CSF or GM-CSF with bone marrow stromal cell transplan-
tation promotes axonal regeneration and functional recovery after
SCI [54,55]. Several authors reviewed the therapeutic properties
of MSCs and reported that these cells are able to secrete, among
others, CNTF, MCP-1 and GM-CSF [21,22,23]. We also detected
a slight tendency of increased expression of anti-inflammatory
cytokines IFN-c, IL-10, and pro-inflammatory IL-1b after MSC
injection but the levels concerned and the differences with the
control group are insignificant. All together these cytokines and
trophic factors could have a beneficial effect after SCI on the
reduction of the inflammatory reaction, cell death and tissue
protection, but regarding the low difference we have seen in their
expression in injured tissue between MSC-grafted and control rats,
they cannot be the only explanation for an important functional
recovery.
Concerning nerve growth factor (NGF), we observed a high and
statistically significant increase of its expression in MSC-grafted
animals compared to controls, which totally agrees with the results
obtained after MSC iv transplantation in traumatic brain injury
[56]. NGF has been shown to play a role in protecting neuronal
injured tissue from toxic events, inducing regrowth, repair and
reorganization of neuronal connections [57,58,59] but also
stimulating neurogenesis [22,60]. NGF is also known to activate
monocytes, macrophages and microglia in CNS by increasing
their phagocytic activity [57,61,62]. After CNS injury, NGF is
secreted by microglia [63], but we believe that the higher NGF
expression observed in the injured tissue in MSC-grafted spinal
cord results from its secretion by MSC themselves. Indeed, we
show that they do express NGF in vitro, and that they secrete NGF
as demonstrated by our Elisa results. BDNF, to a lesser extent, is
also expressed and secreted by MSCs in vitro. These results are in
accordance with the literature [22,64,65]. We however can not
rule out the possibility that the elevated expression of NGF found
in the grafted tissue could be due to endogenous cells being
stimulated by injected MSCs. BDNF is beneficial to SCI repair,
both for axonal growth and tissue protection [66,67]. If no
significant effect on axonal regrowth with GAP-43 staining was
obtained in our MSC-treated rats, we however show a neuropro-
tective effect of our transplanted cells. Actually, one of the most
documented effects of MSC treatment after SCI is the reduction of
cavity formation or tissue sparing, which is frequently reported
without the demonstration of an axonal regrowth-associated effect
[45,68,69,70,71]. Bearing in mind the large neuroprotective and
repair-inducing effect of NGF, its higher expression could thus
partially explain the largest amount of spared tissue in MSC
grafted rats.
Among the molecules secreted by MSCs, pro-angiogenic factors
like VEGF [72] are interesting to study in SCI as blood supply is
essential for repair of damaged tissue. Furthermore, tissue sparing
is often associated with stimulation of angiogenesis. VEGF/
PDGF-stimulated angiogenesis results in lesion size reduction and
Figure 7. Axonal regrowth. (A–B) GAP43 immunoreactivity on transversal spinal cord sections, 28 days after SCI, in injured + MSC (A) and injured-
only (B) groups. Sections were taken at the lesion site. (C) Image analysis doesn’t show a significant difference (Student’s t-Test, p=0,23) in the
percentage of total lesioned area immunoreactive for GAP43 between treated (2,96 6 0,35 %) and control (2,25 6 0,44 %) groups
doi:10.1371/journal.pone.0039500.g007
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In our study, we only detect a slight tendency of increase in the
expression of VEGF after MSC graft, which is probably not
sufficient to be responsible of the higher blood vessel density that
we found. As it has been previously shown, MSCs have the
capacity to provide other trophic support for angiogenesis such as
bFGF, BMP-2, angiogenin, MCP-1 or IL-6 [72,75]. Matrix
metalloproteinases also facilitate angiogenesis by helping the
invasion of endothelial cells [76,77]. MSCs could also be able to
increase endothelial cell survival in an injured environment via
other paracrine secretions like anti-apoptotic molecules [20,21,23].
Throughout the literature, MSCs show differences in their
survival and integration within host tissue as well as in their effects
on repair. We explain these discrepancies by the difference
between MSCs themselves. Indeed, variations in the morphology,
behavior and characteristics have been shown depending on the
number of passages, the plating densities and the duration of
culture [78]. It has been reported that subpopulations of MSCs
with different properties do exist [64,79]. Using different markers,
some authors were able to select subpopulations of MSCs [80].
Furthermore, it has been shown that MSCs in the bone marrow
have at least two developmental origins, one of them being the
neural crest [81,82]. Also, it has been reported that deprivation of
serum [83,84] or hypoxia culture conditions [85] modify MSC
characteristics. The existence of such subpopulations with
distinctive properties is reinforced by differences in MSC
properties in culture or in their post-graft effect, even more for
human MSC from different donors [86,87]. So, we believe the
way a heterogeneous population of MSCs is cultured selects some
subpopulations with different characteristics and properties.
In conclusion, despite differences in the mechanisms and effects
of MSC graft after SCI, their beneficial effect on functional
recovery remains constant. We confirm an early significant
behavioral improvement in MSC-transplanted rats, which is likely
due to their paracrine secretions, as no cells could be found within
the host. We also show a tissue sparing effect and a higher blood
vessel density in the injured site, which can also play a beneficial
role in tissue sparing and functional recovery by improving blood
flow in the lesion [88]. These effects are mediated at least partially
through the important NGF secretion, but, in regard of the large
array of factors MSCs are able to secrete, we cannot exclude the
effect of other molecular actors we didn’t study here. Additional
work is needed to study and further characterize the paracrine
effect of MSCs after SCI.
Materials and Methods
1. Mesenchymal stem cell isolation, culture and
characterization.
MSCs were harvested from Wistar adult female rats. After
sacrifice, femurs and tibias were aseptically removed and bone
marrow flushed from each piece with approximately 5 ml culture
Figure 8. Blood vessel quantification. (A–B) RECA-1 immunohistological staining on longitudinal sections of MSC-treated (A) and control
vehicle-treated (B) spinal cords. Scale bar: 500 mm. (C) Blood vessel quantification within the lesioned site reveals a significant increase in MSC treated
rats compared to control-vehicle treated ones. *p,0.05.
doi:10.1371/journal.pone.0039500.g008
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culture flask in Dulbecco’s Modified Eagle Medium (Invitrogen)
supplemented with 10% of foetal bovine serum (Invitrogen). The
culture medium was changed once per day for three days in order
to remove non-adherent cells. Then the culture medium was
changed twice a week and cells were passaged when they reached
confluence. The enrichment in MSCs was made simply by several
passages due to their preferential adherence to plastic. Cells were
characterized by their specific surface antigen expression with
immunocytochemistry against CD90 (+), CD271 (= p75NGFr) (+)
[34], CD11b (2) and CD45 (2). Their multipotency was
monitored by in vitro differentiation into adipocytes and osteocytes
[35,84]. After fixation with 4% paraformaldehyde, the adipogenic
differentiation was evaluated by accumulation of lipid vacuoles
and staining with Oil Red O (Sigma) and the osteogenic
differentiation was visualized by Alizarin Red S staining (Sigma)
of matrix mineralization associated with osteoblasts. We consid-
ered that the culture contained 95% of MSCs after 4 to 5 passages.
2. Animals
50 adult female Wistar rats from the animal facility of the
University of Liege were used for this study (6250 g). All
experiments were conducted according to the ethical laws and
regulations of Belgian National Fund for Scientific Research. The
project research has been approved by the ethical commission for
animal use of the University of Liege, Belgium. Animals were
subdivided into 3 experimental groups (Table 1):
1. Spinal cord injured rats without treatment (n=10) = Injured
only.
2. Spinal cord injured rats injected with fresh culture medium
without serum (vehicle) (n=20) = Injured + vehicle-treated.
3. Spinal cord injured rats injected with a suspension of MSCs in
fresh culture medium without serum (n=20) = Injured
+MSC-treated.
Animals were housed individually with water and food ad
libitum. One week before the beginning of the experiments,
animals were placed daily in the different surroundings of the
behavioural tests, to get accustomed to them.
3. Spinal cord injury procedure and animal care
Animals were anaesthetized by inhalation of Isoflurane (Fore-
neH, Abbott, Queenborough, Kent, England) 2 to 3% in a flow of
1 L/minute of oxygen. The compression injury was performed as
described by Vanicky et al. [89]. Briefly, a 2-French Fogarty
arterial embolectomy catheter (Edwards Lifesciences LLC, Irvine,
CA, USA) was inserted in the epidural space at the T10 level and
moved rostrally for 2 metameric levels before being inflated with a
distilled water volume of 15 ml and left in place during 5 minutes.
The balloon was then deflated and carefully removed. Skin and
muscle were carefully closed in two layers. 1mL of NaCl 0.09%
was injected subcutaneously to prevent dehydration during the
time animals recover from anaesthesia. Antibiotic (amoxicilline-
clavulanic acid) was administrated by intraperitoneal (ip) injection
after the surgery to prevent urinary tract infection. Animals had
their bladder manually emptied twice daily until recovery of
micturition and were carefully inspected for weight loss, dehydra-
tion and autophagia.
4. Mesenchymal stem cell injection procedure
72 hours before injection, MSCs were cultured in D-MEM
(Invitrogen) without serum to induce the expression of nestin, a
protein expressed by neural stem cells. This was performed in
order to favour their fate towards neural stem cells [84], which
could further support their integration within the host tissue. In
order to label MSCs, 1.10
26M of 5-Bromo-29-deoxyuridine
(BrdU) was added to the culture medium during this period.
The culture medium was changed every 24 hours. MSCs were
injected 7 days after injury. We used passage 12 MSCs. After
reaching confluence, cells were detached and collected in D-MEM
without serum. The number of cells per mL was calculated and
cells were diluted in order to obtain 1.10
6 cells in an injection
volume of 500 mL. Animals were anaesthetized by inhalation of
Isoflurane (ForeneH, Abbott, Queenborough, Kent, England) 2 to
3% in a flow of 1 L/minute of oxygen. Intravenous 24 GA
catheter (Becton Dickinson) was inserted in one of the caudal vein
and the cell suspension was injected with the UltraMicroPump
(UMP-3) and SYS-Micro4 controller (World Precision Instru-
ments) in a flow rate of 50 mL/min. The catheter was removed
2 min after the end of injection to avoid cell loss during its
withdrawal. The last drop of cell suspension collected from the
catheter was put back in culture on polyornithine-coated glass
coverslips to assess cell viability at the time of the injection
procedure.
5. Behavioural analyses
Following SCI, locomotion and sensorimotor skills were
monitored as follows, twice a week, during 3 weeks:
Open field locomotor test. The Basso, Beattie and
Bresnahan (BBB) locomotor rating scale [90] was used. Rats were
observed walking freely in an open field and scores were attributed
by two blinded observers according to the recovery of hind limb
movements.
Grid navigation test. This test was used to assess the deficit
in descending motor control. The animals had to cross 5 times a
1 m long grid with round metal bars separated from 4 cm and a
score was attributed by two blinded observers according to the
recovery of hind limb movements: 0. Hindlimb drag, no foot
placement; 1. Consistent foot faults, foot miss and fall through wire
mesh; 2. Consistent foot faults, foot slip off grid after accurate step
and fall through wire mesh; 3. Accurate foot placement on grid but
toes do not grip; 4. Normal course over grid with gripping toes.
For statistical analysis, we used a GLMM model (generalized
linear mixed models) and p,0.05 was considered statistically
significant.
Table 1. Animal distribution in the various experimental groups.
Injured + MSC -treated Injured + Vehicle -treated Injured only
4 weeks survival after SCI N=11 N=11 N=10
10 days survival after SCI N=9 N=9 /
doi:10.1371/journal.pone.0039500.t001
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Tissue processing. Animals were deeply anaesthetized with
pentobarbital (200 mg/kg) ip injection (Nembutal, CEVA Sante ´
Animale, Libourne, France) and perfused with 250 mL of NaCl
0.09% (4uC) followed by 500 mL of 4% paraformaldehyde (4uC)
in 0.1 M phosphate buffer saline (PBS, pH 7.4). The spinal cords
were rapidly dissected out and post-fixed in the same fixative for
24 h at 4uC and then kept for 48 h in 30% sucrose for
cryoprotection. Two tissue blocks of 0.75 cm length were taken
from both sides of the lesion epicentre. Tissue blocks were then
either transversely, either longitudinally, cryo-sectioned in 20 mm
serial sections, mounted on superfrost
+ glass slides and stored at
220uC until used.
Tissue staining. To analyze the lesion extension, we
performed Eosin – Luxol fast blue histological staining. We
calculated the ratio between the measured injured area and the
entire area of the spinal cord slice on serial transversal sections,
covering a tissue bloc of 1,5 cm centered on the lesion epicenter.
We used ANOVA followed by the Scheffe ´’s post-hoc test. p,0.05
was considered statistically significant.
BrdU immunostainings. Sections were fixed with 4% PFA
for 5 min. After 1 TBS (Tris buffered saline) rinse, tissue sections
were first permeabilized with 0.3% Triton in TBS for 15 min at
RT. They were then rinsed 365 min in TBS at 37uC, and further
incubated in HCl 2N for 30 min at 37uC followed by Na
Tetraborate 0.1 M pH 8.5 for 10 min at 37uC. After 3 TBS rinses,
they were incubated in a blocking buffer (1% BSA and 10% goat
normal serum in 0.3% Triton X-100-TBS) for 1h, and thereafter
overnight at 4uC in the BrdU antibody diluted in the blocking
buffer (containing 3% of normal goat serum instead of 10%). After
3 TBS20.05% Tween20 and one TBS rinses, the sections were
incubated for 1 h at RT with Alexa FluorH488 goat anti-rat (1/
1000, Invitrogen), rinsed 3 times in TBS20.05%Tween20, and
once in TBS. Sections were finally coverslipped with VectashieldH
with DAPI mounting medium (Labconsult). Negative controls
were obtained by omission of the primary antibody.
In order to check the maintenance of BrdU within MSCs
throughout their divisions, we performed a BrdU immunocyto-
chemistry on P12 MSCs as follows: P12-MSCs were cultured in D-
MEM +10% FBS until 60% confluence. Cells were then rinsed
once with PBS and cultured in D-MEM without FBS + 1.10
26 M
BrdU for 3 days (as it was done for the cells used for in vivo
transplantation). The medium was renewed every day. Then,
MSCs were placed again in D-MEM +10% FBS for 3, 7 and
21 days. During this period, the culture was maintained by
medium changes and passages (0, 1 and 6 passages, respectively).
At each delay, cells were detached and placed on glass coverslips
during a few hours in order to perform a BrdU immunostaining.
Fluorescent immunocytochemistry. Cells were cultured
on polyornithine (Sigma-Aldrich, Schnelldorf, Germany) coated
glass coverslips and fixed during 5 minutes in 4% PFA or in 4%
PFA buffered in 50 mM sodium borate at pH 9.5 for Nestin
immunostaining. For BrdU staining, cells were fixed with 4% PFA
for 5 min, incubated in HCl 2N at 37uC for 30 min and
neutralized in sodium tetraborate 0,1 M for 10 min. After 3
PBS rinses, cells were incubated in a blocking buffer (1% BSA and
10% of appropriate normal serum in PBS +0.3% Triton X-100)
for 1 h, and thereafter overnight at RT in the primary antibody
diluted in the blocking buffer (1% BSA and 3% appropriate
normal serum in PBS +0.3% Triton X-100). After 3 PBS20.05%
Tween20 and one PBS rinses, cells were incubated for 1 h at RT
with the secondary antibody diluted in PBS +1% of appropriate
normal serum, rinsed 3 times in PBS +0.05% Tween20, and once
in PBS. Coverslips were finally turned over on glass slide using
VectashieldH with DAPI mounting medium (Labconsult). Nega-
tive controls were obtained by omission of the primary antibody.
DAB immunostainings. Tissues were fixed with 4% PFA for
5 min, then incubated in a 0.3% H2O2, 0.1% Na azide solution in
PBS for 20 min at RT to reduce endogenous peroxydase activity.
Nonspecific binding was prevented by 1h incubation in 3%
normal serum and 1% bovine serum albumin solutions in PBS
+0.2% triton. Sections were then incubated overnight at RT with
the primary antibody. After 3 PBS rinses, they were incubated
with their respective secondary biotinylated antibodies (Vector
Laboratories) diluted and centrifuged in PBS with 1% BSA and
2% of rat serum, for 1 h at RT. Then sections were incubated 1 h
with the avidin-biotin-peroxydase complex (Vector Laboratories),
diluted 1/1000 in PBS and the immunostaining revealed with
3,39-diaminobenzidine.
Antibodies. The primary antibodies used for immunostain-
ing were the following: mouse anti-CD90 (1/100, AbCam), rabbit
anti-CD45 (1/100, AbCam), mouse anti-CD11b (1/200, AbD
Serotec), mouse anti-Nestin (1/200, Chemicon), rat anti-BrdU (1/
100, AbD serotec), rabbit anti-NGF (1/100, AbCam), rabbit anti-
p75NGFr (1/500, AbCam), mouse anti-RECA-1 (1/200, Ab-
Cam), chicken anti-BDNF (1/250, R&D Systems). Secondary
antibodies were rhodamine- or FITC-coupled donkey anti-mouse,
rhodamine- or FITC- donkey anti-rabbit, rhodamine donkey anti-
chicken (1/500, Jackson Immunoresearch), Alexa FluorH488 goat
anti-rat (1/1000, Invitrogen) or Alexa FluorH488 donkey anti-
mouse and anti-rabbit (1/500, Invitrogen) for immunofluores-
cence, and biotinylated goat anti-rabbit and horse anti-mouse (1/
500, Vector Laboratories) for DAB immunostainings.
Image analysis. Immunoreactivity and tissue stainings were
examined and captured using an Olympus AX70 microscope
equipped with an Olympus DP50 digital camera and an Olympus
FSX100 microscope. Images were analysed by AnalySIS software
(Soft Imaging System, Olympus) for spared tissue quantification.
For GAP-43 immunostaining quantification, bright field images of
transversal sections of the ‘‘lesion-caudal’’ tissue block were taken
and pictures were converted to gray scale. A threshold intensity of
gray-colored staining was fixed for each slice. Then, a surface
covering the entire lesion area was selected (= total lesion area).
Thereafter, immunostaining was quantified within non-overlap-
ping successive fields covering the total lesion area (= total stained
area) using Analysis software (Olympus). Data were expressed as
the percentage of total stained area (pixel) per total lesioned area
(pixel). The results represent averages from 5 ‘‘injured only’’ rats
and 6 ‘‘injured + MSC’’ rats. The statistical significances between
injured-grafted and injured only groups were assessed using a
Student t-test.
Blood vessel quantification. We performed RECA-1 im-
munostainings on longitudinal sections of spinal cords 10 days
after injury (3 days after MSC graft for treated animals). The
epicentre zone was encircled and the number of blood vessels
counted within the zone. The statistical significances between
injured-grafted and injured only groups were assessed using a
Student t-test.
7. Cytokine array
We used a custom Rat Cytokine Antibody Array kit
(RayBiotech, Norcross, Georgia, USA). Animals were deeply
anaesthetized with pentobarbital (200 mg/kg) ip injection and
perfused with 250 mL NaCl 0,09% at 4uC. Tissue block of 1 cm
length and centred on the injury epicentre was dissected out and
crushed into lysis buffer (RayBiotech) containing protease inhib-
itors (complete mini, Roche) on ice. After protein dosage (BCA
protein assay reagent kit, Pierce), 200 mg of total proteins were
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protocol supplied with the kit. The cytokine array membranes
were scanned with a Las-4000 luminescent image analyser
(Fujifilm, Tokyo, Japan). The intensity of the signal was measured
with the Quantity One 1-D Analysis software (Bio-RAD Labora-
tories, Hercules, CA). The results were expressed as the mean
relative signal intensity, i.e. the ratio of sample signal intensity/
positive control signal intensity. Each signal intensity of positive
controls and samples were normalized by background substrac-
tion. The statistical significances between injured-grafted and
injured only groups were tested using a Student t-test.
8. NGF – BDNF Quantification in the MSC-conditioned
medium
NGF and BDNF levels were measured by enzyme-linked
immunosorbent assay according to the manufacturer’s protocol
(ChemiKine Nerve Growth Factor Sandwich ELISA kit CYT304
and ChemiKine Brain Derived Neurotrophic Factor, Sandwich
ELISA kit CYT306, Chemicon). The conditioned media from 2
distinct cultures of rat MSCs at passage 12 were harvested and
concentrated using Amicon Ultra-15 centrifugal filter units
(Millipore). 100 ml of these two concentrated media (M1 and
M2) were used for the assay.
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